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Abstract: Vaccination is one of the most important tools to protect pigs against infection with porcine
reproductive and respiratory syndrome virus 1 (PRRSV-1). Although neutralizing antibodies are
considered to represent an important mechanism of protective immunity, anti-PRRSV antibodies, in
particular at subneutralizing concentrations, have also been reported to exacerbate PRRSV infection,
probably through FcγR-mediated uptake of antibody-opsonized PRRSV, resulting in enhanced
infection of, and replication in, target cells. Therefore, we investigated this pathway using sera
from an animal experiment in which vaccine-mediated enhancement of clinical symptoms was
observed. Three groups of six pigs were vaccinated with an inactivated PRRSV vaccine based on
the PRRSV-1 subtype 3 strain Lena and challenged after a single or a prime-boost immunization
protocol, or injected with PBS. We specifically tested if sera obtained from these animals can enhance
macrophage infections, viral shedding, or cytokine release at different dilutions. Neither the presence
of neutralizing antibodies nor general anti-PRRSV antibodies, mediated an enhanced infection,
increased viral release or cytokine production by macrophages. Taken together, our data indicate that
the exacerbated disease was not caused by antibodies.
Keywords: PRRSV-1; inactivated vaccine; homologous challenge; in vivo; antibody-dependent
enhancement (ADE) of disease; monocyte-derived macrophages
1. Introduction
Antibody-dependent enhancement (ADE) of infection is a phenomenon that has been associated
with many different viruses, such as lactate dehydrogenase elevating virus [1], HIV-1 [2,3], dengue
virus [4,5], Japanese encephalitis virus (JEV) [6], and FMDV [7–9]. For some of these infections, this
in vitro phenomenon has been associated with immunity-enhanced disease. A typical example of
this is Dengue [5]. On the other hand, for other infections, even closely related ones such as JEV,
no association of ADE antibodies with adverse vaccine effects or pre-existing immunity have been
reported [6]. Typically, ADE was found at subneutralizing concentrations, at which antibodies are
binding to the virus but are not sufficiently numerous to mediate neutralization. This binding facilitates
viral uptake through FcRs, typically for IgG isotype antibodies. Alternatively, the antibodies can
be specific for viral epitopes that are non-neutralizing. Theoretically, if the virus can replicate in
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FcR-expressing cells such as monocytes and macrophages, this would increase the viral replication
and viral load, leading to more severe symptoms. Alternatively, or in addition, immune complexes
can trigger an increased release of cytokines, which could potentially exacerbate symptoms [10,11]
or indirectly downregulate an antiviral response [12,13]. This depends on the predominant antibody
isotype and its preferential binding to either inhibitory or stimulatory FcRs.
ADE of disease in PRRSV was first described by Yoon et al., who investigated the enhancement of
infection of alveolar macrophages and also found increased viremia and shedding of virus in vivo,
after serum transfer to reach subneutralizing antibody titers [14]. They found that neutralizing
antibodies with titers of 4 log2 were protective, but titers of 1 log2 increased viremia. In this study,
the prototype PRRSV-2 strain VR-2332 was used. The same authors subsequently tested antibodies
against this strain also for their ability to enhance the infection with heterologous strains and found a
strain-dependent enhancement [15]. Further in vitro studies indicated the involvement of all three
Fcγ receptors [16–18]. Using monoclonal antibodies, the Gp5/M complex was identified as a possible
target for ADE antibodies [19].
Despite these studies, it is important to note that to our knowledge, enhanced disease after
experimental vaccination with live attenuated vaccines (LAV) has not been observed, although the
challenge infections were frequently performed in absence of neutralizing antibodies. There is also
no indication that re-exposure with an antigenically distinct PRRSV strain that is not neutralized can
result in enhanced disease [20–22].
However, in a vaccination challenge experiment, we found evidence for vaccine-induced enhanced
disease for PRRSV. The pigs were vaccinated with an inactivated, homologous vaccine, followed
by a challenge with the Lena strain. Lena represents a subtype 3 PRRSV-1 that emerged in Eastern
Europe and stands out as a highly pathogenic PRRSV strain [23]. Following PRRSV challenge, some
of the vaccinated animals developed more severe clinical symptoms and pneumonia, compared to
mock-vaccinated animals. We, therefore, tested the sera from such animals for their ability to enhance
infection of monocyte-derived macrophages (MDMs) and increase the amount of virus that would be
released from the MDMs as well as to induce cytokine release. We used MDMs because they are a
well-established cell culture model in PRRSV research, and allowed us to perform this research without
having to sacrifice an unnecessarily large number of animals.
2. Materials and Methods
2.1. Animal Experiments
The vaccination experiments were performed at the Faculty of Veterinary Medicine at Ghent
University, Merelbeke, Belgium. The local Ethical and Animal Welfare Committee of the Faculty of
Veterinary Medicine of Ghent University approved the animal experiment (EC 2012/082, approval
date: 11/07/2012).
Eighteen five-week-old pigs were obtained from a conventional, PRRSV-free farm in Belgium
and tested to be free of PRRSV, porcine circovirus-2, and swine influenza virus by immunoperoxidase
monolayer assay (IPMA). The piglets were randomly divided into three groups of six animals.
The groups were either vaccinated once (“Lena 1x”), four weeks before the challenge, or twice
(“Lena 2x”) at eight and four weeks before challenge (Appendix A, Figure A1). The age of the pigs at
the time of the first immunization was six and ten weeks old. For the vaccination, binary ethyleneimine
(BEI, Sigma-Aldrich, St. Louis, MO, USA)-inactivated Lena, grown on MARC-145 cells, formulated in
commercial oil-in-water adjuvant (Suvaxyn, Zoetis Animal Health [24]; 1 mL/1 mL; 108 TCID50/dose),
was used. The pigs in the control group received 1 mL PBS with 1 mL adjuvant intramuscularly (i.m.)
at eight and four weeks before the challenge. All animals were challenged by intranasal inoculation of
105 TCID50 PRRSV Lena at 14 weeks of age. The challenge virus had been passaged three times on
alveolar macrophages. At 42 days post-challenge (dpc), all pigs were euthanized by slow injection of
an overdose of sodium pentobarbital 20% in the jugular vein.
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The production of the reference immune sera against PRRSV strain Lena was performed at
the IVI [25]. Briefly, three six-week-old SPF pigs (Swiss Landrace, in-house bred and reared) were
infected with 5 × 105 TCID50 Lena intranasally. Due to severe symptoms, one pig had to be euthanized
seven days post-infection (dpi), while the other two pigs recovered from the infection and were kept
until 52 dpi. Then, they were sacrificed, and we collected sera to establish the assay for detection of
ADE antibodies.
2.2. Monocyte-Derived Macrophages
Peripheral blood mononuclear cells (PBMCs) were prepared with venous blood from 80–150 kg
healthy pigs (Swiss Landrace). The pigs were held under specific pathogen-free (SPF) conditions.
PBMCs were obtained by density centrifugation (Ficoll-Paque Plus, GE Healthcare Europe, Glattbrugg,
Switzerland). From these, the monocytes were MACSTM-sorted on an LS-column (Miltenyi Biotec,
Bergisch Gladbach, Germany) with the anti-CD172a monoclonal antibody (mAb), clone 74-22-15A (own
production, hybridoma kindly provided by Prof. Armin Saalmüller, University of Vienna, Austria) and
anti-mouse IgG-microbeads (Miltenyi Biotec). The purity of the sorted cells was 78–87%, depending
on the experiment. The cells were cultured in phenol red-free Dulbecco’s modified Eagle’s medium
(DMEM; Gibco, Thermo Fisher Scientific, Waltham, MA, USA), complemented with 10% fetal bovine
serum (FBS; Thermo Fisher Scientific), and 20 U/mL porcine CSF-1 (own production [26]), plated at
0.5 × 106 cells/mL and left to differentiate into monocyte-derived macrophages (MDMs) for 4 days at
39 ◦C, 5% CO2 [26].
2.3. Virus Preparation
Virus was grown on MDMs until a cytopathic effect (CPE) of 50% was reached. Then, the infected
macrophages were frozen at −80 ◦C to lyse the cells. Subsequently, the cell lysate was centrifuged
at 2000× g at 4 ◦C for 20 min to clarify the lysate and the viral titer was determined by titration on
4-day-old MDMs using IPMA with the mAb SR30-A (RTI, Brookings, SD, USA), directed against the
PRRSV nucleocapsid (N). The tissue culture infective dose of 50% per mL (TCID50/mL) was calculated.
2.4. Quantification of Viremia and Viral Shedding In Vitro
The viral quantification was performed by IPMA. A 10-fold serial dilution of serum (Figure 1)
or cell culture supernatant (Figure 6) were incubated on 4-day-old MDMs for 48 h at 39 ◦C, 5% CO2.
Then, the incubation media was removed, and the cells were fixed with 80% acetone for 10 min at
room temperature (RT). The cells were washed with PBS, and for the detection of PRRSV-infected
cells in the IPMA, the mAb 13E2 (own production, [27]; Figure 1) or mAb SR30-A (Figure 6)
and horseradish-peroxidase conjugated polyclonal goat anti-mouse antibodies (Dako AS, Glostrup,
Denmark) were used.
2.5. Quantification of Neutralizing Antibodies in Positive Control Sera
Neutralizing antibody titers of the positive control serum were determined on a porcine kidney
cell line, PK15, which expresses CD163 and CD169 (“PK15+/+”) [28]. PK15+/+ cells, passage 10, were
seeded at 2.5 × 105 cells/mL in 96 well plates. Cells were cultured overnight at 37 ◦C, 5%CO2, in PK15+/+
medium (44% DMEM, 44% RPMI, 10% horse serum, 1% non-essential amino acids, and 1% Na-pyruvate
(all Thermo Fisher Scientific)). For the rest of this experiment, 1000 U/mL penicillin/streptomycin
(Thermo Fisher Scientific) were added to the medium. A serial 1:2 dilution of the immune sera in
medium was performed in duplicate. An equal part of medium, containing 100 TCID50 (titer was
determined on PK15+/+ cells), was added to the diluted immune sera. The virus–serum mixtures
were allowed to form complexes for 30 min at 37 ◦C. Virus without immune sera was incubated
alongside the virus–immune sera and served as a positive control for its continued infectivity. After this
pre-incubation, the medium was removed from the PK15+/+ cells, and immune complexes or virus
were allowed to infect the cells for 1 h at 37 ◦C, 5% CO2. The cells were washed once with warm PBS
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containing Mg2+ and Ca2+ (“PBS+/+”, Thermo Fisher Scientific) and fresh medium was added. After
48 h at 37 ◦C, 5%CO2, an IPMA assay was performed, as described above. The neutralizing titers were
calculated as 50% neutralizing dose (ND50).
2.6. Antibody Responses during Vaccination Experiment
Serum samples were heat-inactivated for 30 min at 56 ◦C prior to testing. PRRSV-specific antibodies
were detected by IPMA, as previously described [29,30]. Briefly, MARC-145 cells were seeded in
96-well plates, inoculated with PRRSV Lena virus and incubated for 24 h at 37 ◦C, 5% CO2. Then, the
culture medium was removed and cells were washed with PBS and dried (1 h at 37 ◦C) After fixation
with 4% paraformaldehyde (PFA, w/v; Polysciences, Warrington, PA, USA) for 10 min at RT, 1% H2O2
in methanol was added to the cells for 5 min, and cells were subsequently washed twice with PBS.
Serial fourfold dilutions of the sera were added and incubated for 1 h at 37 ◦C. Plates were washed
three times with PBS plus 1% Tween 80 and polyclonal goat anti-swine IgG/HRP (Dako; dilution 1:500)
was added for 1 h (37 ◦C). The plates were washed again three times and 50 µL of a substrate solution
(5% 3-amino-9-ethylcarbazole in 0.05 M acetate buffer, pH 5, with 0.05% H2O2) was added to each well
and incubated for 20 min at RT. Then, the reaction was stopped by removing the substrate solution and
replacing it with acetate buffer. Presence of anti-PRRSV antibodies was indicated by the deeply red
stained cytoplasm of infected MARC-145 cells. The results were determined by examination with a
microscope [29].
PRRSV-specific neutralizing antibodies from the vaccination challenge trial were titrated using a
virus neutralization (VN) test on MARC-145 cells, as previously described [24].
2.7. ADE of Macrophage Infection
MDMs were prepared as described above, plated in 48-well plates, and left to differentiate for
72 h. We infected MDMs to achieve ca. 30% infected MDMs after 16 h incubation. It is noteworthy that
in determining this MOI, one has to take into account that the virus will be incubated with the sera
for 30 min at 37 ◦C, and a higher MOI is necessary to get 30% infected cells, compared to using the
virus stock in absence of serum pre-incubation. Sera were heat-inactivated (56 ◦C, 30 min) and serially
diluted in DMEM containing 1% FBS and 1000 U/mL Pen/Strep. Then, the sera were pre-incubated with
MOI 0.02 of Lena for 30 min at 37 ◦C to allow immune complexes to form. One aliquot of the lowest
dilution of each serum (1:30), was also incubated with cell lysate for mock controls of the respective
immune serum. Directly after this pre-incubation, the medium was removed from the MDMs and
replaced by the immune complex sera. Cells were infected in triplicates and infection was allowed
for 1 h at 39 ◦C, 5% CO2. Then, the cells were washed twice with warm PBS+/+ and post-infection
medium (DMEM, supplemented with 10% FBS, 20 U/mL M-CSF and 1000 U/mL Pen/Strep) was added.
After 16 h at 39 ◦C, 5% CO2, the supernatants were collected and stored at −80 ◦C. The cells were
harvested by 20 min incubation at RT with Accutase (Innovative Cell Technologies, San Diego, CA,
USA). Then, cold PBS supplemented with 4.7 mM EDTA was added and the cells gently removed from
the plates for flow cytometry staining.
2.8. Flow Cytometry
Briefly, cells were fixed with 4% PFA in PBS (Sigma-Aldrich). Then, the cells were washed
and permeabilized with 0.1% saponin (AppliChem, Darmstadt, Germany) in PBS (w/v). For the
detection of PRRSV, we used the mAb SR30-A for 20 min, followed by goat anti-mouse IgG1-AF647
(Molecular Probes, Thermo Fisher Scientific) for 15 min. Each reagent was diluted in 0.3% saponin in
PBS (w/v) and incubations were done on ice. After a final washing step, the cells were resuspended
in CellWash® (Becton Dickinson, Allschwil, Switzerland) and acquired with a FACSCanto (Becton
Dickinson). The data were analyzed with the FlowJo software (Tree Star, Ashland, OR, USA). Doublets
were excluded in FSC A/W and SSC A/W, and then a gate was set on the big cells in FSC-A/SSC-A, to
exclude debris and dead cells.
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2.9. ELISA
Cytokines were measured in the supernatants of infected macrophages. The following cytokines
were tested: porcine IL-1β/IL-1F2 (Kit: DY681), IL-6 (Kit: DY686), IL-10 (Kit: DY693B), IL-12/IL-23
p40 (Kit: DY912), and TNF (Kit: DY690B; all kits were obtained from R&D Systems, Minneapolis,
MN, USA).
2.10. Statistical Analysis
Statistical analyses were performed with repeated measures (RM) 2-way ANOVA, followed by
Tukey’s post hoc analysis. p < 0.05 was considered to be statistically significant. If a different statistical
test was used, it is mentioned in the figure legends. Statistical analysis was performed with Prism 6
software (GraphPad Software, San Diego, CA, USA).
3. Results
3.1. Viremia and PRRSV Neutralization Titers after Infection of Naïve Animals for Generation of the Reference
Immune Serum
After the infection of three pigs with PRRSV Lena, the animals developed a viremia within 24 h
of infection that peaked at 5–6 dpi. Due to the severity of clinical symptoms, which included the
inability to get up, one of the animals had to be euthanized at eight dpi, while the other two animals
slowly gained control over the virus infection. They were symptom-free after 17–18 dpi, although their
viremia lasted until 28 or 35 dpi. The surviving pigs developed detectable neutralizing antibody titers
by 21 or 28 dpi. At 52 dpi, they had ND50 titers of 1:11 for pig 2 and 1:17 for pig 3. The dynamics
of the viremia have previously been published [25]. The serum of pig 3 served as “positive control
serum” in the presented experiments (Figures 5 and 6).
3.2. Vaccination with an Inactivated Virus and Homologous Challenge
We have recently developed a novel inactivated vaccine against PRRSV-1, subtype 1 strains,
that showed promising protective results [31]. At the time of these experiments, no vaccine was yet
available against the highly pathogenic strain Lena and, consequently, we tested the efficacy of a
similarly prepared vaccine against Lena. Conventionally raised pigs were vaccinated once (Lena 1x) or
twice (Lena 2x) with inactivated Lena virus and subsequently challenged with PAM-grown Lena. All of
the animals in the vaccination trial developed viremia (Figure 1). The pigs from the Lena 1x group
developed a significantly higher viremia than the control group early during the infection (at 3dpc), but
never peaked as high as the other groups. Meanwhile, the animals that had been vaccinated twice were
able to reduce their viral titers one week before the control group, but they also peaked significantly
higher in viremia than the Lena 1x pigs, and one pig had to be euthanized due to the severity of
clinical symptoms. Nevertheless, after 10 dpc, both vaccinated groups had a significantly reduced
viremia compared to the unvaccinated pigs; the Lena 2x group even already at 7 dpc. All surviving
pigs were able to eliminate the virus from their blood, though each group had at least one animal that
experienced a rebound of viremia.
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virus (PRRSV)-negative pigs and IPMA. Pigs in the control group received two injections of PBS + 
adjuvant, eight and four weeks before the challenge. Group “Lena 1x” was vaccinated once with 
inactivated Lena, four weeks before the challenge. The group “Lena 2x” was vaccinated twice at eight 
and four weeks before the challenge. dpc—days post-challenge, wpc—weeks post-challenge. 
Numbers (1451–1465) represent the individual pigs. Solid rectangles around pig numbers mean they 
have been used in all ADE experiments, dashed rectangles mean that their sera have also been further 
analyzed, but not in all ADE experiments. The black line is the average of each group. Statistical 
analysis was performed with RM 2-way ANOVA, followed by Tukey’s multiple comparison test. 
Statistically significant values are highlighted in grey in the table under the graphs. 
3.3. Body Temperature and Respiratory Disease Score 
Surprisingly, despite the presence of neutralizing antibodies, all animals developed clinical signs 
of infection upon challenge with Lena (Figures 2 and 3). Even more unexpectedly, four piglets in the 
vaccinated groups showed severe symptoms (fever up to 41.8 °C, hypothermia down to 37.6 °C, 
tremor, convulsions, diarrhea). These symptoms were so severe in the case of one pig in the “Lena 
2x” group (pig #1453) that it had to be euthanized at 7 dpc. 
The respiratory symptoms were scored as follows: 0 = normal breathing (20–40 breaths per 
minute); 1 = mild dyspnea and/or tachypnea (40–60 breaths per minute) when stressed by holding 
Figure 1. Viremia of Lena-vaccinated pigs foll i ologous challenge infection. Viremia was
determined by titration PAMs collect d from porcine r productive and respiratory syndrome virus
(PRRSV)-negative pi s and IPMA. Pigs in the co trol group received two injectio s of PBS + adjuvant,
eight and four weeks bef re the challenge. Group “Lena 1x” was vaccinated once with inactivated Lena,
four weeks before the challenge. The group “Lena 2x” was vaccinated twice at eight and four weeks
before the challenge. dpc—days post-challenge, wpc—weeks post-challenge. Numbers (1451–1465)
represent the individual pigs. Solid rectangles around pig numbers mean they have been used in all
ADE experiments, dashed rectangles mean that their sera have also been further analyzed, but not in
all ADE experiments. The black line is the average of each group. Statistical analysis was performed
with RM 2-way ANOVA, followed by Tukey’s multiple comparison test. Statistically significant values
are highlighted in grey in the table under the graphs.
3.3. Body Temperature and Respiratory Disease Score
Surprisingly, despite the presence of neutralizing antibodies, all animals developed clinical signs
of infection upon challenge with Lena (Figures 2 and 3). Even more unexpectedly, four piglets in
the vaccinated groups showed severe symptoms (fever up to 41.8 ◦C, hypothermia down to 37.6 ◦C,
tremor, convulsions, diarrhea). These symptoms were so severe in the case of one pig in the “Lena 2x”
group (pig #1453) that it had be euthaniz t 7 dpc.
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Figure 2. Body temperature after challenge. Control, Lena 1x, and Lena 2x: Colored lines represent 
individual animals and thick black lines represent the mean value for each group. Temperature >40 
°C was considered as fever (dotted line on upper panel). dpc—days post-challenge. Statistical analysis 
was performed with an ordinary 2-way ANOVA, followed by Tukey’s multiple comparison test. 
Statistically significant values are highlighted in grey in the table under the graphs. 
Figure 2. Body temperature after challenge. Control, Lena 1x, and Lena 2x: Colored lines represent
individual animals and thick black lines represent the mean value for each group. Temperature >40 ◦C
was considered as fever (dotted line on upper panel). dpc—days post-challenge. Statistical analysis was
performed with an ordinary 2-way ANOVA, followed by Tukey’s multiple comparison test. Statistically
significant values are highlighted in grey in the table under the graphs.
The respiratory symptoms were scored as follows: 0 = normal breathing (20–40 breaths per
minute); 1 = mild dyspnea and/or tachypnea (40–60 breaths per minute) when stressed by holding
the pig for 45 s; 2 = mild dyspnea and/or tachypnea (40–60 breaths per minute) at rest; 3 = moderate
dyspnea and/or tachypnea (60–80 breaths per minute) when stressed; 4 = moderate dyspnea and/or
tachypnea (60–80 breaths per minute) at rest; 5 = severe dyspnea and/or tachypnea (>80 breaths per
minute) when stressed; 6 = severe dyspnea and/or tachypnea (>80 breaths per minute) at rest.
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Figure 3. Respiratory disease scores after challenge. Control, Lena 1x, and Lena 2x: Colored lines 
represent individual animals and thick black lines represent the mean value for each group. Scores: 0 
= normal; 1 = mild dyspnea and/or tachypnea when stressed; 2 = mild dyspnea and/or tachypnea at 
rest; 3 = moderate dyspnea and/or tachypnea when stressed; 4 = moderate dyspnea and/or tachypnea 
at rest; 5 = severe dyspnea and/or tachypnea when stressed; 6 = severe dyspnea and/or tachypnea at 
rest. dpc—days post-challenge. Statistical analysis was performed with an ordinary 2-way ANOVA, 
followed by Tukey’s multiple comparison test. Statistically significant values are highlighted in grey 
in the table under the graphs. 
3.4. PRRSV-Specific and PRRSV-Neutralizing Antibody Titers 
All animals in the Lena 1x group developed PRRSV antibodies (Figure 4 left panels), but 
neutralizing antibodies were not found or only transiently detectable (Figure 4 right panels). After 
the challenge, all animals in this group developed neutralizing antibodies. The animals in the Lena 
2x group developed high titers of neutralizing antibodies after the booster, but the titer of one of these 
animals (pig #1453) declined before the challenge. This pig had to be euthanized because of the 
severity of its symptoms upon challenge. 
Over the entire course of the experiment, the titers of neutralizing antibodies in the booster-
vaccinated group remained high. Nonetheless, the presence of these neutralizing antibodies did not 
appear to have a beneficial effect on the level of the viremia (Figure 1). 
Figure 3. Respiratory disease scores after challenge. Control, Lena 1x, and Lena 2x: Colored
lines represent individual animals and thick black lines represent the mean value for each group.
Scores: 0 = normal; 1 = mild dyspnea and/or tachypnea when stressed; 2 = mild dyspnea and/or
tachypnea at rest; 3 = moderate dyspnea and/or tachypnea when stressed; 4 = moderate dyspnea and/or
tachypnea at rest; 5 = severe dyspnea and/or tachypnea when stressed; 6 = severe dyspnea and/or
tachypnea at rest. dpc—days post-challenge. Statistical analysis was performed with an ordinary 2-way
ANOVA, followed by Tukey’s multiple comparison test. Statistically significant values are highlighted
in grey in the table under the graphs.
3.4. PRRSV-Specific and PRRSV-Neutralizing Antibody Titers
All animals in the Lena 1x group developed PRRSV antibodies (Figure 4 left panels), but
neutralizing antibodies were not found or only transiently detectable (Figure 4 right panels). After the
challenge, all animals in this group developed neutralizing antibodies. The animals in the Lena 2x
group developed high titers of neutralizing antibodies after the booster, but the titer of one of these
animals (pig #1453) declined before the challenge. This pig had to be euthanized because of the severity
of its symptoms upon challenge.
Over the entire course of the experiment, the titers of neutralizing antibodies in the
booster-vaccinated group remained high. Nonetheless, the presence of these neutralizing antibodies
did not appear to have a beneficial effect on the level of the viremia (Figure 1).
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Figure 4. PRRSV-specific IPMA (left) and VN (right) antibodies before and after challenge 105 TCID50 
PRRSV Lena. Control pigs received two injections of PBS in adjuvant, at eight and four weeks before 
the challenge. Group “Lena 1x” was vaccinated once, four weeks before the challenge. Group “Lena 
2x” received a prime/booster vaccination at eight and four weeks before the challenge. PRRSV-specific 
antibodies were detected by IPMA. PRRSV-neutralizing antibodies were detected by a virus 
neutralization assay (VNT). Colored lines with symbols represent individual pigs. Solid black lines 
represent the average of each group and dashed black lines represent the average of the control group. 
v—vaccination; numbers represent individual pig numbers. Solid rectangles around pig numbers 
mean they have been used in all ADE experiments, dashed rectangles mean their sera have also been 
further analyzed, but not in all ADE experiments. Statistical analysis was performed with RM 2-way 
ANOVA, followed by Tukey’s multiple comparison test. The comparison was: Lena 1x vs. Control, 
and Lena 2x vs. Control. p < 0.05 was considered statistically significant and is represented by *. 
3.5. ADE of Macrophage Infection 
In the next step, we tested whether the sera would influence the infection of MDMs. To this end, 
we chose an infectious dose of Lena that would yield between 25% and 50% infected cells after 16 h 
of incubation. To avoid the impact of inter-experiment variation, all sera of one pig, including the 
pre-vaccination time point, were tested together with a defined negative control (serum from an SPF 
pig) and a selected potentially “positive” control (Lena-infected pigs with neutralizing antibodies). 
Figure 4. PRRSV-specific IPMA (left) and VN (right) antibodies before and after challenge 105
TCID50 PRRSV Lena. Control pigs received two injections of PBS in adjuvant, at eight and four
weeks before the challenge. Group “Lena 1x” was vaccinated once, four weeks before the challenge.
Group “Lena 2x” received a prime/booster vaccination at eight and four weeks before the challenge.
PRRSV-specific antibo ies were detected by IPMA. PRRSV-neutralizing antibodies were detected by a
virus neut ti n a say (VNT). C lored lines with symbols present in ividual pigs. Solid black lines
represent th aver g of each group and dashe l lines repr sent the average of the control group.
v—vaccination; numbers represent individual pig nu bers. Solid rectangles around pig numbers
mean they have been used in all ADE experiments, dashed rectangles mean their sera have also been
further analyzed, but not in all ADE experiments. Statistical analysis was performed with RM 2-way
ANOVA, followed by Tukey’s multiple comparison test. The comparison was: Lena 1x vs. Control,
and Lena 2x vs. Control. p < 0.05 was considered statistically significant and is represented by *.
3.5. ADE of Macrophage Infection
In the next step, we tested whether the sera would influence the infection of MDMs. To this end,
we ch se an infectious dose of Len that would yield between 25% and 50% infected cells aft r 16 h
of incubation. To avoid the impact of in er-experiment variation, all sera f one pig, including the
pre-vaccination time point, were tested together with a defined negative control (serum from an SPF
pig) and a selected potentially “positive” control (Lena-infected pigs with neutralizing antibodies).
Virus pre-incubated with the positive control serum resulted in more infected cells at a dilution of 1:150 in
7/7 experiments run in triplicate. In some, but not all, experiments with the same serum, ADE was also
found at the 1:750 dilution (Figure 5). This constitutes a dilution of factor 13 to 68 beyond the neutralizing
titer. The dilution of 1:30 was enhancing the macrophage infection in two of the three shown experiments,
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and once acting in a neutralizing manner. While these experiments indicate that ADE could be happening
with PRRSV immune sera, the effect was mild and varied considerably between experiments.
In the sera from the randomly selected control animal #1445, we occasionally found evidence
of ADE, but this was also observed before challenge and was not consistently found at particular
dilutions nor did it appear to be titratable (Figure 5). In the two sera from the randomly selected Lena
1x group, we did not find any consistent evidence for ADE. The serum with neutralizing antibodies at
10 dpc had a neutralizing activity also on MDMs (Figure 5).
From the Lena 2x group, we selected four sera randomly to test in the ADE assay (Figure 5).
Pig #1453 appeared to have developed detectable ADE activity at very high serum dilutions after the
first vaccination, but this was not found with the sera from the other pigs nor with the sera from the
Lena 1x group. Furthermore, with the sera collected later, apparent ADE was again found at the two
time points post-challenge. However, this activity did not follow a titration-dependent increase and
decline, indicating that it was not solely dependent on one factor. The observation that this was not
found with the other sera from this group led us to the conclusion that no ADE activity was found
in the Lena 2x group. However, with the other three pigs in this group, we found that sera with
neutralizing activity reduced the infectivity of MDMs in most cases (Figure 5).
Viruses 2019, 11, x FOR PEER REVIEW 11 of 17 
 
p ig  # 1 4 4 5  -  C o n tro l
%
 P
R
R
S
V
 p
o
s
0
2 0
4 0
6 0
8 0
1 0 0
p o s  (5 2 d p i)
n e g  (S P F )
0dpv1
0dpv2
0 d p c
5 d p c
1 0 d p c
7 d p c
D a ta  o n  g ra p h s :
1 :30
1 :150
1 :750
1 :3 '7 50
1 :1 8 '7 50
1 :9 3 '7 50
p ig  # 1 4 5 7  -  L e n a  1 x
%
 P
R
R
S
V
 p
o
s
0
2 0
4 0
6 0
8 0
1 0 0
p ig  # 1 4 5 8  -  L e n a  1 x
0
2 0
4 0
6 0
8 0
1 0 0
Sidak's
#1445 0dpv1 
vs. 0dpv2
0dpv1 
vs. 0dpc
0dpv1 
vs. 5dpc
0dpv1 
vs. 10dpc
neg
vs. pos
1:30 ns ns * ns *
1:150 ** ns * ns *
1:750 ns ns ns ns ****
1:3750 * ns ns * ns
1:18750 ns ns ns ns ns
1:93750 ns ns ns ns ns
0dpv2 0dpc 5dpc 10dpc pos
Ab-titer [log2] 0 0 5.32 11.32 nd
VN-titer [log2] 0 0 0 0 3.46
Viremia [log10] 0 0 3.3 2.8 0
Dunnett's multiple comparisons test
Sidak's
#1457 0dpv1 
vs. 0dpv2
0dpv1 
vs. 0dpc
0dpv1 
vs. 5dpc
0dpv1 
vs. 10dpc
neg
vs. pos
1:30 ns ns ns *** ***
1:150 ns ns ns ns ****
1:750 ns ns ns ns ***
1:3750 ns ns ns ns ns
1:18750 ns ns ns ns ns
1:93750 ns ns ns ns ns
0dpv2 0dpc 5dpc 10dpc pos
Ab-titer [log2] 0 17.32 11.32 15.32 nd
VN-titer [log2] 0 0 0 4 3.46
Viremia [log10] 0 0 3.8 0 0
Dunnett's multiple comparisons test Sidak's
#1458 0dpv1 
vs. 0dpv2
0dpv1 
vs. 0dpc
0dpv1 
vs. 5dpc
0dpv1 
vs. 10dpc
neg
vs. pos
1:30 ns ns ns ns *
1:150 ns ns ns ns *
1:750 ns ns ns ns ****
1:3750 * ns ns ns ns
1:18750 ns * ns ns ns
1:93750 ns ns ns ns ns
0dpv2 0dpc 5dpc 10dpc pos
Ab-titer [log2] 0 9.32 9.32 19.32 nd
VN-titer [log2] 0 0 0 1 3.46
Viremia [log10] 0 0 3.3 1.13 0
Dunnett's multiple comparisons test
A
 
Figure 5. Cont.
Viruses 2019, 11, 829 11 of 16
Viruses 2019, 11, x FOR PEER REVIEW 12 of 17 
 
p ig  # 1 4 5 3  -  L e n a  2 x
%
 P
R
R
S
V
 p
o
s
0
2 0
4 0
6 0
8 0
1 0 0
p ig  # 1 4 5 5  -  L e n a  2 x
%
 P
R
R
S
V
 p
o
s
0
2 0
4 0
6 0
8 0
1 0 0
p ig  # 1 4 5 6  -  L e n a  2 x
0
2 0
4 0
6 0
8 0
1 0 0
Sidak's
#1453 0dpv1 
vs. 0dpv2
0dpv1 
vs. 0dpc
0dpv1 
vs. 5dpc
0dpv1 
vs. 7dpc
neg
vs. pos
1:30 ns * ns * *
1:150 ns * ns *** *
1:750 ns ns * ** ns
1:3750 *** ns ns ns ns
1:18750 ** ns ns ** ns
1:93750 ** ns *** **** ns
0dpv2 0dpc 5dpc 7dpc pos
Ab-titer [log2] 7.32 11.32 14.32 15.32 nd
VN-titer [log2] 0 0 0 1.58 3.46
Viremia [log10] 0 0 4.8 4.97 0
Dunnett's multiple comparisons test
p ig  # 1 4 5 4  -  L e n a  2 x
0
2 0
4 0
6 0
8 0
1 0 0
Sidak's
#1454 0dpv1 
vs. 0dpv2
0dpv1 
vs. 0dpc
0dpv1 
vs. 5dpc
0dpv1 
vs. 10dpc
neg
vs. pos
1:30 ns ** ns *** *
1:150 ns **** ns **** *
1:750 ns * ns * ****
1:3750 ns ns ns ns ns
1:18750 ns * ns ** ns
1:93750 ns ns ns ns ns
0dpv2 0dpc 5dpc 10dpc pos
Ab-titer [log2] 9.32 10.32 15.32 17.32 nd
VN-titer [log2] 0 5.58 5 9 3.46
Viremia [log10] 0 0 5.3 2.97 0
Dunnett's multiple comparisons test
Sidak's
#1455 0dpv1 
vs. 0dpv2
0dpv1 
vs. 0dpc
0dpv1 
vs. 5dpc
0dpv1 
vs. 10dpc
neg
vs. pos
1:30 ns **** **** **** *
1:150 ns ns ** ** *
1:750 ns ns ns ns ns
1:3750 ns ns ns ns ns
1:18750 ns ns ns ns ns
1:93750 ns ns ** ns ns
0dpv2 0dpc 5dpc 10dpc pos
Ab-titer [log2] 9.32 18.32 18.32 15.32 nd
VN-titer [log2] 0 6.58 5.58 7.58 3.46
Viremia [log10] 0 0 3.8 0.93 0
Dunnett's multiple comparisons test Sidak's
#1456 0dpv1 
vs. 0dpv2
0dpv1 
vs. 0dpc
0dpv1 
vs. 5dpc
0dpv1 
vs. 10dpc
neg
vs. pos
1:30 ns **** **** **** *
1:150 ns *** ns ns *
1:750 ns ns * ns ns
1:3750 ns ns ns ns ns
1:18750 ns ns ns ns ns
1:93750 ns ns ns ns ns
0dpv2 0dpc 5dpc 10dpc pos
Ab-titer [log2] 7.32 21.32 16.32 16.32 nd
VN-titer [log2] 0 6.58 7 7.58 3.46
Viremia [log10] 0 0 5.07 0.5 0
Dunnett's multiple comparisons test
B
 
Figure 5. Macrophage infection in the presence of immune sera. Sera of several randomly selected 
pigs from the different groups were tested for their ability to enhance the infection of monocyte-
derived macrophages (MDMs). Serial dilutions (1:30 to 1:93,750) of the sera were pre-incubated with 
Lena. Then, MDMs were infected in triplicates and tested PRRSV N-protein after 16 h by flow 
cytometry. In A, the results for pig #1445, from the control group, which received 2 injections of PBS 
+ adjuvant, as well as the results for pigs #1457 and #1458, from the “Lena 1x” group, which were 
Figure 5. Macrophage infection in the presence of immune sera. Sera of several randomly selected pigs
from the different groups were tested for their ability to enhance the infection of nocyte-derived
macrophages (MDMs). Serial dilutions (1:30 to 1:93,750) of the sera were re-incubated with Lena.
Then, MDMs were infected in triplicates and tested PRRSV N-protein after 16 h by flow cytometry.
In (A), the results for pig #1445, from the control group, which received 2 injections of PBS + adjuvant,
as well as the results for pigs #1457 and #1458, from the “Lena 1x” group, which were vaccinated once,
is shown. In (B). the results for pigs #1453–1456, from the “Lena 2x” group, which were vaccinated
twice, is shown. Bars show mean with SD. dpv—days post-vaccination, dpc—days post-challenge,
dpi—days post-infection; 0dpv1 = eight weeks before challenge, 0dpv2 = four weeks before challenge.
Statistical analysis was performed with ordinary 2-way ANOVA, followed by Dunnett’s multiple
comparison test or Sidak’s post hoc test, as indicated. Green highlighting indicates a neutralizing
effect, while orange highlighting indicates an enhancing effect. Symbols: * = p < 0.05, ** = p < 0.01,
*** = p < 0.001, **** = p < 0.0001.
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In conclusion, these tests did not permit us to identify ADE as a possible cause of enhanced
disease. Furthermore, the MDM assay system based on nucleoprotein measurement of infectivity was
not robust in terms of its reproducibility. We, therefore, tested if viral progeny from these cultures was
influenced by the different sera (Figure 6). In three independent cultures, the positive control serum
induced only once increased viral shedding at a 1:30 dilution. Curiously, we found that, indeed, the
serum of pig #1445 of 0dpv2 led to increased shedding of virus. It is the same serum and dilution that
had also led to a higher percentage of infected MDMs, while the pig had not been exposed to any
vaccine or virus, yet. We also observed two small, yet statistically significant, increases for pig #1457
with the sera 0dpv2, 1:30, and 0dpc, 1:3750, and a reduced titer for 10dpc, 1:18,750, all of which did not
correspond to any increase or reduction in infection of MDMs. None of the SNs of the sera tested for
pig #1458 differed significantly from the control. For pig #1454 from the Lena 2x group, we saw a clear
reduction in the viral titers at 1:30 10 dpc.
Viruses 2019, 11, x FOR PEER REVIEW 13 of 17 
 
va cinated once, s shown. In B. the results for pigs #1453–1456, from the “Lena 2x” group, which 
were vaccinated twice, is shown. Bars show m an with SD. dpv—days post-vaccination, pc—days 
post-challenge, dpi—days post-infectio ; 0dpv1 = eight weeks before challenge, 0dpv2 = four weeks 
before challenge. Statistical analysis was performed wi h ordinary 2-way ANOVA, followed by 
Dunnett’s multiple comparison test or Sidak’s post hoc test, as indicated. Green highlighting indicates 
a neutralizing effect, while orange h ghl ghting indicates an enhancing effect. Symbols: * = p < 0.05, ** 
= p < 0.01, *** = p < 0.001, **** = p < 0.0001. 
1
:3
0
1
:1
5
0
1
:7
5
0
1
:3
7
5
0
1
:1
8
7
5
0
1
:9
3
7
5
0
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
c o n tro ls  1
D ilu tio n  o f  s o u rc e  s e ru m
T
C
ID
5
0
/m
l
neg
p o s  (5 2 d p i)
1
:3
0
1
:1
5
0
1
:7
5
0
1
:3
7
5
0
1
:1
8
7
5
0
1
:9
3
7
5
0
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
p ig  # 1 4 5 7  -  L e n a  1 x
D ilu tio n  o f  s o u rc e  s e ru m
T
C
ID
5
0
/m
l
** *
*
1
:3
0
1
:1
5
0
1
:7
5
0
1
:3
7
5
0
1
:1
8
7
5
0
1
:9
3
7
5
0
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
c o n tro ls  2
D ilu tio n  o f  s o u rc e  s e ru m
neg
p o s  (5 2 d p i)
*
1
:3
0
1
:1
5
0
1
:7
5
0
1
:3
7
5
0
1
:1
8
7
5
0
1
:9
3
7
5
0
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
p ig  # 1 4 5 4  -  L e n a  2 x
D ilu tio n  o f  s o u rc e  s e ru m
* *
*
0dpv1 1 0 d p c  (p ig  # 1 4 5 3 : 7 d p c )5 d p c0 d p c0dpv2
1
:3
0
1
:1
5
0
1
:7
5
0
1
:3
7
5
0
1
:1
8
7
5
0
1
:9
3
7
5
0
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
p ig  # 1 4 5 8  -  L e n a  1 x
D ilu tio n  o f  s o u rc e  s e ru m
1
:3
0
1
:1
5
0
1
:7
5
0
1
:3
7
5
0
1
:1
8
7
5
0
1
:9
3
7
5
0
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
p ig  # 1 4 4 5  -  C o n tro l
D ilu tio n  o f  s o u rc e  s e ru m
****
1
:3
0
1
:1
5
0
1
:7
5
0
1
:3
7
5
0
1
:1
8
7
5
0
1
:9
3
7
5
0
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
c o n tro ls  3
D ilu tio n  o f  s o u rc e  s e ru m
neg
p o s  (5 2 d p i)
1
:3
0
1
:1
5
0
1
:7
5
0
1
:3
7
5
0
1
:1
8
7
5
0
1
:9
3
7
5
0
1 0
2
1 0
3
1 0
4
1 0
5
1 0
6
1 0
7
1 0
8
p ig  # 1 4 5 3  -  L e n a  2 x
D ilu tio n  o f  s o u rc e  s e ru m
*
*
*
 
Figure 6. Impact of sera on virus titers in MDM cultures. Serially diluted immune sera were pre-
incubated with Lena. Then, MDMs were infected with these immune complex mixtures, washed, and 
incubated for a total of 16 h. The supernatants were titrated in triplicates. Controls 1–3 show the viral 
titers when PRRSV-Ab-negative serum (neg) or PRRSV-immune serum (pos, from 52 dpi) were used 
as immune sera. Pig #1445, from the control group, had not been immunized before challenge. Pigs 
#1457 and #1458, from the “Lena 1x” group, were vaccinated once with BEI-inactivated Lena + 
adjuvant, and pig #1454, from the “Lena 2x” group, was vaccinated twice with the same vaccine. 
dpv—days post-vaccination, dpc—days post-challenge, dpi—days post-infection; 0dpv1 = eight 
weeks before challenge, 0dpv2 = four weeks before challenge. Statistical analysis was performed with 
ordinary 2-way ANOVA, followed by Tukey’s multiple comparison test. Within each dilution, the 
sera from different time points were compared with the “initial serum” (neg or 0dpv1). Symbols: * = 
p < 0.05, ** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. Color of the asterisks denote to which serum they 
belong. 
4. Discussion 
PRRSV mutates frequently, and because of a generally restricted heterologous protection, quick 
development of protective vaccines is of great importance to the pig production community. 
Immunization with an inactivated field strain could, in principle, serve that purpose; by employing 
a high antigen payload and a potent adjuvant, we previously demonstrated that such vaccines can 
have a protective value [24,31]. This was the basis for employing such a vaccine approach for Lena, 
Figure 6. Impact of sera on virus titers in MDM cultures. Serially diluted immune sera were
pre-incubated with Lena. Then, MDMs were infected with these immune complex mixtures, ashed,
and incubated for a total of 16 h. The supernatants were titrated in triplicates. Controls 1–3 show the
viral titers when PRRSV-Ab-negative serum (neg) or PRRSV-immune serum (pos, from 52 dpi) were
used as immune sera. Pig #1445, from the control group, had not been immunized before challenge.
Pigs #1457 and #1458, from the “Lena 1x” group, were vaccinated once with BEI-inactivated Lena
+ adjuvant, and pig #1454, from the “Lena 2x” group, was vaccinated twice with the same vaccine.
dpv—days post-vaccination, dpc—days post-challenge, dpi—days post-infection; 0dpv1 = eight weeks
before challenge, 0dpv2 = four weeks before challenge. Statistical analysis was performed with ordinary
2-way ANOVA, followed by Tukey’s multiple comparison test. Within each dilution, the sera from
different time points were compared with the “initial serum” (neg or 0dpv1). Symbols: * = p < 0.05,
** = p < 0.01, *** = p < 0.001, **** = p < 0.0001. Color of the asterisks denote to which serum they belong.
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We also checked the presence of cytokines in the supernatants that were derived with the sera of
0 dpc and 5 dpc, dilutions 1:30 to 1:750, of the pigs #1445, #1458, #1453, and #1454; but were unable to
detect any induction of IL-1β, IL-6, IL-10, IL-12, or TNF (data not shown).
In summary, neither the neutralizing effect of the sera nor the slight enhancement of MDM-infection
translated into consistently strong effects regarding the viral shedding or any effect on cytokine release.
4. Discussion
PRRSV mutates frequently, and because of a generally restricted heterologous protection,
quick development of protective vaccines is of great importance to the pig production community.
Immunization with an inactivated field strain could, in principle, serve that purpose; by employing a
high antigen payload and a potent adjuvant, we previously demonstrated that such vaccines can have
a protective value [24,31]. This was the basis for employing such a vaccine approach for Lena, which
is a particularly highly pathogenic (HP) PRRSV strain that emerged recently in Eastern Europe [23]
and has aﬄicted it since. Therefore, we vaccinated two groups of pigs either once or twice with
BEI-inactivated Lena. While the vaccination was found to be successful in terms of the ability to
induce anti-PRRSV antibodies after a single injection or even to induce neutralizing antibodies after
the prime/boost vaccination, the vaccinations were disappointing for their protective capacity. In fact,
there were even signs of enhanced disease in some of the vaccinated animals. This lack of protection
in the presence of neutralizing antibodies is in direct conflict with several previous reports, where
the adoptive transfer to reach neutralizing antibody serum levels was protective [14,32–34]. It also
contradicts many studies which observed a positive correlation between neutralizing antibodies and
control of viremia [20–22]. This discrepancy may be due to strain-specific characteristics or unknown
environmental factors affecting the vaccinated pigs. Nevertheless, it is not possible to attribute this
to the inactivated vaccine as this has been previously found to be efficacious with other strains of
PRRSV [31,35].
Due to this unexpected outcome, we investigated the possible involvement of ADE antibodies in
the deteriorative clinical outcome of this vaccination trial. We tested the sera for the capacity to mediate
ADE in porcine MDMs, a natural target cell of PRRSV, which constitutively expresses CD16 and CD64.
The results demonstrate that immune sera that neutralized virions on a cell line assay also neutralized
the infection of the MDMs. This neutralizing effect was only lost at a dilution of 1:150/1:750. Beyond
this dilution, we only rarely observed a very slight enhancement of MDM infection. We did, however,
also detect the occasional statistical significance in enhancement or neutralization of infection for sera
that were still naïve or had no detectable levels of neutralizing antibodies, respectively. Nevertheless,
the enhancing effects were mild and often did not titrate. It is important to bear in mind that PRRSV
infectivity is influenced by many factors in the serum, not only by antibodies. Furthermore, statistical
significance and biological significance are not synonymous.
Alternative explanations for the enhanced disease observed in the vaccinated groups could be
that FcRs on other cells, such as monocytes and dendritic cells, could be targeted by the immune
complexes, resulting in infection and possibly inflammatory reactions. Furthermore, an involvement
of the complement system or vaccine-primed T cells needs to be considered. Complement has been
proposed to play a role for ADE of West Nile virus (WNV) [36] and HIV [37,38]. In our setup, the
heat-inactivation of the sera prevented us from testing such effects. Recently, Bordet et al. showed a
strain-specific increased secretion of IFNγ by polarized T helper 1 (Th1) cells in response to the Lena
strain [39]. It is possible that the vaccination(s) in our experiment primed these T cells, leading to
enhanced inflammatory responses, which exacerbated the clinical symptoms.
5. Conclusions
We conclude that ADE of macrophage infection mediated solely by antibodies is not a feature
in this vaccination challenge experiment and cannot explain the lack of protection or even enhanced
disease following the homologous challenge with the subtype 3 PRRSV-1 strain Lena. Also, sera
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from naturally infected pigs with the same strain of PRRSV had no or only a weak ADE activity.
Furthermore, there are now a total of four experimental studies demonstrating the protective role of
antibodies against PRRSV, and that this effect is correlated to neutralizing activity [14,32–34]. Therefore,
future vaccine design should continue to focus on the induction of broadly neutralizing antibodies.
With respect to the employment of inactivated vaccines, the present work also demonstrates that
extrapolations from one PRRSV-1 strain to another can be risky. While such vaccines, if prepared
appropriately, can be protective [24,31], the outcome with the Lena strain was detrimental despite
induction of neutralizing antibodies. This is adding one more piece to the puzzling immunology
of PRRS.
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